What services does JCC Group provide for pharmaceutical and biologics manufacturers?

JCC Group offers end-to-end regulatory consulting services for pharmaceutical and biologics companies, including 21 CFR Part 211 cGMP compliance, Quality Management System (QMS) design, validation strategy, FDA inspection readiness, supplier qualification, data integrity assessments, and harmonization with ICH international standards (Q7, Q8, Q9, Q10, and Q11). Our consultants partner with clients across the full product lifecycle — from facility start-up and clinical-stage manufacturing through commercial production and post-approval changes.

What types of companies does JCC Group work with?

We support a broad spectrum of clients, including emerging biotech startups, contract manufacturers (CMOs/CDMOs), mid-size pharmaceutical companies, global drug manufacturers, biologics and cell & gene therapy developers, and international manufacturers exporting to the U.S. market. Whether you are launching your first product or managing a multi-site global operation, our services scale to fit your needs.

What is 21 CFR Part 211, and who must comply?

21 CFR Part 211 establishes the FDA's Current Good Manufacturing Practice (cGMP) requirements for finished pharmaceuticals. It applies to any company involved in manufacturing, processing, packaging, labeling, or holding human and veterinary drug products distributed in the United States — including drug substance and drug product manufacturers, contract facilities, and repackagers.

How does JCC Group help companies achieve 21 CFR Part 211 compliance?

We provide comprehensive support including cGMP gap assessments, QMS design and implementation, SOP and documentation development, equipment qualification (IQ/OQ/PQ), process and cleaning validation, quality control laboratory compliance, change control programs, CAPA systems, and mock FDA inspections. Our team builds compliance programs tailored to your operations — not generic templates.

Does JCC Group support biologics manufacturers under 21 CFR Part 211?

Yes. While biologics are also governed by 21 CFR Part 600-series regulations, Part 211 still applies to many aspects of biologic drug product manufacturing. We support biologics manufacturers across monoclonal antibodies, recombinant proteins, vaccines, cell and gene therapies, and biosimilars — addressing both small-molecule and large-molecule complexities.

What are ICH guidelines, and why do they matter?

The International Council for Harmonisation (ICH) develops globally recognized standards for pharmaceutical quality, safety, and efficacy. Compliance with ICH guidelines — especially Q7 (API GMP), Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), Q10 (Pharmaceutical Quality System), and Q11 (Drug Substance Development) — is essential for companies seeking global market access and harmonized regulatory approval across the U.S., EU, Japan, and other ICH regions.

How does JCC Group help companies align with ICH standards?

Our consultants integrate ICH principles into every aspect of our consulting work. We design Pharmaceutical Quality Systems aligned with ICH Q10, implement quality risk management frameworks per ICH Q9, support development activities under Q8/Q11, and ensure API manufacturing aligns with ICH Q7 — enabling clients to meet both FDA expectations and global harmonized requirements simultaneously.

Can JCC Group build a Quality Management System (QMS) from scratch?

Absolutely. We design and implement complete Quality Management Systems for new facilities, startups, and companies transitioning from clinical-stage to commercial manufacturing. Our QMS deliverables include Quality Manuals, SOPs, work instructions, forms, Master Production Records, Batch Production Records, change control systems, and integrated documentation control platforms.

Does JCC Group provide ongoing QMS maintenance and support?

Yes. Beyond initial implementation, we offer long-term advisory services to keep your QMS current with evolving regulations, support periodic management reviews, conduct internal audits, manage CAPA effectiveness checks, and provide regulatory intelligence updates. Many clients engage us as their long-term regulatory partner rather than a one-time consultant.

What happens during a mock FDA inspection conducted by JCC Group?

Our mock inspections replicate real FDA methodology — including facility walkthroughs, document reviews, employee interviews, and front-room/back-room dynamics. We assess your operations against 21 CFR Part 211, your QMS, and applicable ICH standards, then deliver a detailed report with prioritized findings, root cause insights, and clear remediation recommendations.

Can JCC Group help if we received a Form 483 or FDA Warning Letter?

Yes — rapid-response remediation is one of our core specialties. Our team conducts immediate root cause investigations, develops comprehensive CAPA plans, drafts written responses that meet FDA expectations, and manages the remediation process from start to finish. We have helped clients successfully close significant findings and restore compliance under tight deadlines.

QMS Implementation - J&J Consulting Group- FDA Regulatory Compliance

Creating and Establishing a Quality Management System (QMS) Across FDA-Regulated Industries

A Comprehensive Implementation Guide by J&J Compliance Consulting Group (JJCC Group)

A Quality Management System (QMS) is the formalized framework of policies, procedures, processes, and records that a manufacturer uses to consistently produce safe, effective, and compliant products. For companies operating in FDA-regulated sectors, a QMS is not optional documentation; it is the operational backbone that demonstrates control over every stage of the product lifecycle, from raw material sourcing to distribution and post-market surveillance. Whether you manufacture pharmaceuticals, medical devices, dietary supplements, food, cosmetics, or tobacco products, the U.S. Code of Federal Regulations (CFR), Title 21, defines the minimum quality expectations your organization must meet.

Establishing a QMS from the ground up requires translating broad regulatory language into concrete, auditable practices tailored to your specific industry. The applicable 21 CFR Part differs by product category, and so do the technical requirements, terminology, and inspection focus areas. J&J Compliance Consulting Group (JJCC Group) specializes in building, implementing, and sustaining QMS programs that satisfy these distinct regulatory regimes. Below, we explain the QMS requirements for each industry, the specific 21 CFR citations that govern them, and how JJCC Group delivers end-to-end services to bring your operation into a state of audit readiness and continuous compliance.

The Universal Building Blocks of an Effective QMS

Regardless of industry, a robust QMS is constructed from a common set of foundational elements. JJCC Group ensures each of these pillars is designed, documented, and embedded into daily operations:

Document and Records Control:

A controlled hierarchy of quality manuals, Standard Operating Procedures (SOPs), work instructions, and forms, with version control, approval workflows, and retention schedules.

Quality Risk Management:

Systematic identification, assessment, and mitigation of risks using tools such as FMEA and ICH Q9 principles, applied to products and processes.

Corrective and Preventive Action (CAPA):

A closed-loop system for investigating deviations, identifying root causes, and verifying that corrections prevent recurrence.

Change Control:

A governed process for evaluating, approving, and documenting changes to facilities, equipment, materials, processes, and documentation.

Training and Competency:

Role-based training programs with documented qualification and ongoing reinforcement to ensure personnel can perform their duties.

Supplier and Vendor Qualification:

Evaluation, approval, and monitoring of suppliers, contract manufacturers, and testing laboratories.

Internal Audits and Management Review:

Scheduled self-inspections and leadership reviews that drive accountability and continuous improvement.

Data Integrity:

Controls ensuring records are Attributable, Legible, Contemporaneous, Original, and Accurate (ALCOA), across paper and electronic systems.

Pharmaceuticals and Drug Products

Governing Regulations: 21 CFR Part 210 (general cGMP for drugs) and 21 CFR Part 211 (cGMP for finished pharmaceuticals). Active pharmaceutical ingredients are additionally guided by ICH Q7.

Drug manufacturers are held to the most rigorous quality expectations under the Current Good Manufacturing Practice (cGMP) regulations. 21 CFR Part 211 prescribes detailed requirements covering organization and personnel, buildings and facilities, equipment, control of components and drug product containers, production and process controls, packaging and labeling, holding and distribution, laboratory controls, records and reports, and returned and salvaged drug products.

JJCC Group QMS Services for Drug Manufacturers

cGMP Quality System Design: Construction of the full SOP architecture mapped directly to each subpart of 21 CFR Part 211, including batch record systems and master production records.
Validation and Qualification: Process validation (stages 1-3), equipment IQ/OQ/PQ, cleaning validation, and analytical method validation aligned with FDA guidance and ICH standards.
Laboratory Controls: Establishment of stability programs, out-of-specification (OOS) investigation procedures, and data integrity controls for laboratory information systems.
CAPA and Deviation Management: Implementation of investigation, root-cause analysis, and CAPA workflows that withstand FDA Form 483 and warning-letter scrutiny.
Annual Product Review: Design of product quality review processes consistent with §211.180(e).

Medical Devices

Governing Regulations: 21 CFR Part 820 (Quality System Regulation). The FDA is harmonizing Part 820 with ISO 13485:2016 through the Quality Management System Regulation (QMSR), so JJCC Group designs systems compliant with both frameworks.

The medical device QMS centers on design controls, a requirement unique to this sector. 21 CFR Part 820 mandates management responsibility, design controls, document controls, purchasing controls, identification and traceability, production and process controls, acceptance activities, nonconforming product handling, CAPA, labeling, handling, storage, distribution, installation, servicing, and statistical techniques.

JJCC Group QMS Services for Device Manufacturers

Design Control and Design History File (DHF): Establishment of design planning, inputs, outputs, review, verification, validation, transfer, and design change procedures per §820.30.
Device Master Record and Device History Record: Construction of the DMR and DHR systems linking specifications to production evidence.
Risk Management to ISO 14971: Integration of device risk management files with the overall QMS.
ISO 13485 / QMSR Transition: Gap assessment and remediation to align legacy Part 820 systems with the harmonized QMSR framework.
Complaint Handling and MDR: Procedures for complaint files and Medical Device Reporting under 21 CFR Part 803.

Dietary Supplements

Governing Regulations: 21 CFR Part 111 (cGMP for dietary supplements) and 21 CFR Part 117 where facility-level food safety provisions apply. Adverse event reporting follows 21 CFR Part 4 and the DSHEA framework.

Dietary supplement manufacturers must establish controls ensuring identity, purity, strength, and composition of their products. 21 CFR Part 111 requires written procedures for quality control operations, master manufacturing records (MMR), batch production records (BPR), component and product testing, and handling of returned products and complaints.

JJCC Group QMS Services for Supplement Manufacturers

Master and Batch Manufacturing Records: Development of compliant MMR and BPR templates capturing every specification and step required under Subpart E.
Identity and Specification Testing: Establishment of component, in-process, and finished-product specifications with scientifically valid test methods.
Quality Control Unit: Definition of QC responsibilities, material review, and disposition authority per §111.65.
Complaint and Adverse Event Systems: Procedures for serious adverse event reporting and product complaint investigation.

Food Manufacturers

Governing Regulations: 21 CFR Part 117 (cGMP, Hazard Analysis, and Risk-Based Preventive Controls for Human Food) under FSMA, with 21 CFR Part 507 applying to animal food and 21 CFR Part 120/123 for juice and seafood HACCP.

Modern food safety management is built on the Food Safety Modernization Act (FSMA), which shifted the focus from reaction to prevention. 21 CFR Part 117 requires a written food safety plan, hazard analysis, preventive controls, supply-chain controls, a recall plan, and current good manufacturing practices, overseen by a Preventive Controls Qualified Individual (PCQI).

JJCC Group QMS Services for Food Manufacturers

Food Safety Plan Development: Authoring of HACCP and HARPC-based plans, including hazard analysis and preventive control determination.
Preventive Controls: Design of process, sanitation, allergen, and supply-chain preventive controls with monitoring, corrective actions, and verification.
Sanitation and Environmental Monitoring: GMP programs, sanitation SOPs, and environmental monitoring for pathogens.
Recall and Traceability: Written recall plans and traceability systems supporting rapid product retrieval.

Cosmetics

Governing Regulations: The Modernization of Cosmetics Regulation Act (MoCRA) of 2022 expanded FDA authority, with cGMP requirements being established under 21 CFR (forthcoming cosmetic GMP rule), supported by existing 21 CFR Parts 700-740 governing cosmetic labeling and prohibited ingredients.

MoCRA introduced mandatory facility registration, product listing, adverse event reporting, safety substantiation, and cosmetic Good Manufacturing Practices. While FDA finalizes its cosmetic GMP regulation, JJCC Group builds QMS programs aligned with ISO 22716 (Cosmetics GMP) and anticipated FDA expectations to ensure a smooth transition once the rule is enforced.

JJCC Group QMS Services for Cosmetic Manufacturers

MoCRA Compliance Program: Facility registration, product listing, and responsible-person designation support.
Cosmetic GMP to ISO 22716: Implementation of production, quality control, personnel, and premises controls.
Safety Substantiation: Documentation files demonstrating adequate substantiation of product safety.
Adverse Event Reporting: Procedures for capturing and reporting serious adverse events as required under MoCRA.

Tobacco Products

Governing Regulations: 21 CFR Part 1100 series and the Tobacco Control Act, with FDA’s proposed Tobacco Product Manufacturing Practice (TPMP) requirements under section 906(e) of the Federal Food, Drug, and Cosmetic Act. Establishment registration and product listing fall under 21 CFR Part 1140 and related provisions.

Tobacco product manufacturers, including makers of cigarettes, cigars, and electronic nicotine delivery systems (ENDS), face an evolving regulatory landscape. The FDA’s proposed manufacturing practice requirements address manufacturing controls, design and process specifications, contamination prevention, and recordkeeping. JJCC Group helps manufacturers prepare for TPMP compliance and supports the quality documentation needed for Premarket Tobacco Product Applications (PMTA).

JJCC Group QMS Services for Tobacco Manufacturers

TPMP Readiness: Manufacturing control systems, process specifications, and contamination prevention programs aligned with proposed FDA requirements.
PMTA Quality Support: Quality and stability documentation supporting premarket application submissions.
Establishment Registration: Support for registration, product listing, and ingredient reporting obligations.
Recordkeeping Systems: Batch records, specifications, and traceability infrastructure for finished tobacco products.

Why Partner with JJCC Group

Building a QMS that survives an FDA inspection requires more than templated documents; it demands deep regulatory expertise applied to the realities of your operation. J&J Compliance Consulting Group delivers a structured implementation methodology: an initial gap assessment against the applicable 21 CFR Part, a prioritized remediation roadmap, hands-on development of your document hierarchy, staff training, and a verification phase that confirms your systems function as designed. Our consultants bring practical experience across SOPs, CAPA, validation, data integrity, FDA 21 CFR Parts 210/211/820, EU GMP, ICH guidelines, and ISO 13485, allowing us to serve multi-product and contract manufacturers operating under several regulatory regimes simultaneously.

From a single SOP to a complete enterprise quality system, JJCC Group scales its services to your needs, helping you move from uncertainty to audit-ready confidence. Through ThecGMPAcademy, we also offer training resources that reinforce a culture of quality long after implementation is complete.